[Betta Pharmaceuticals: Ensartinib Hydrochloride Capsules received a drug registration certificate for postoperative adjuvant treatment indications] On September 3, Beida Pharmaceuticals (300558.SZ) announced that the company received a Drug Registration Certificate issued by the State Drug Administration for ensartinib hydrochloride capsules (trade name: Bemena) for postoperative adjuvant treatment of patients with ALK-positive stage IB to IIIB non-small cell lung cancer. This is the third approved indication for the drug. Ensartinib is a new generation of potent and highly selective ALK inhibitor. Its 2-year disease-free survival rate in postoperative adjuvant therapy reaches 86.4%, and the risk of recurrence is reduced by 80%. This approval will have a positive effect on the company's operating income.